<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(9)</volume><submitter>Bacha Z</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Acute ischemic stroke (AIS) is the most common type of stroke, with increasing incidence and significant healthcare costs. Tenecteplase (TNK), a modified variant of tissue plasminogen activator (tPA), offers advantages such as a longer half-life and single-bolus administration. This meta-analysis evaluates the safety and efficacy of TNK compared to non-thrombolytic management in AIS to guide clinical decision-making.&lt;h4>Methodology&lt;/h4>A comprehensive literature search across major databases identified randomized controlled trials (RCTs) comparing tenecteplase with non-thrombolytic care in ischemic stroke. Data extraction and bias assessment were conducted independently, using RoB 2.0 and the GRADE framework. Meta-analysis was performed using RevMan 5.4.1, applying ran</pubmed_abstract><journal>Brain and behavior</journal><pagination>e70791</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12402402</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Efficacy and Safety of Tenecteplase in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.</pubmed_title><pmcid>PMC12402402</pmcid><pubmed_authors>Afridi A</pubmed_authors><pubmed_authors>Javed J</pubmed_authors><pubmed_authors>Iqbal A</pubmed_authors><pubmed_authors>Ahmed R</pubmed_authors><pubmed_authors>Khan MEW</pubmed_authors><pubmed_authors>Shahid S</pubmed_authors><pubmed_authors>Qasim M</pubmed_authors><pubmed_authors>Khattak F</pubmed_authors><pubmed_authors>Henna F</pubmed_authors><pubmed_authors>Bacha Z</pubmed_authors><pubmed_authors>Ali MA</pubmed_authors><pubmed_authors>Shah MA</pubmed_authors><pubmed_authors>Sheraz M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Efficacy and Safety of Tenecteplase in Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.</name><description>&lt;h4>Introduction&lt;/h4>Acute ischemic stroke (AIS) is the most common type of stroke, with increasing incidence and significant healthcare costs. Tenecteplase (TNK), a modified variant of tissue plasminogen activator (tPA), offers advantages such as a longer half-life and single-bolus administration. This meta-analysis evaluates the safety and efficacy of TNK compared to non-thrombolytic management in AIS to guide clinical decision-making.&lt;h4>Methodology&lt;/h4>A comprehensive literature search across major databases identified randomized controlled trials (RCTs) comparing tenecteplase with non-thrombolytic care in ischemic stroke. Data extraction and bias assessment were conducted independently, using RoB 2.0 and the GRADE framework. Meta-analysis was performed using RevMan 5.4.1, applying ran</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-05-29T15:13:24.457Z</modification><creation>2026-04-08T05:07:33.038Z</creation></dates><accession>S-EPMC12402402</accession><cross_references><pubmed>40891051</pubmed><doi>10.1002/brb3.70791</doi></cross_references></HashMap>